



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Darrell H. Carney, Roger S. Crowther, David J. Simmons,
Jinping Yang and William R. Redin

Application No.: 10/050,692

Group: 1647

Filed: January 16, 2002

Examiner: DeBerry, R.M.

Confirmation No.: 6715

For: STIMULATION OF BONE GROWTH WITH THROMBIN
PEPTIDE DERIVATIVES

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop Sequence, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450	
on <u>7-6-04</u>	<u>Dawse M Myers</u>
Date	Signature
<u>Dawse M Myers</u>	
Typed or printed name of person signing certificate	

TRANSMITTAL OF SUBSTITUTE SEQUENCE LISTING

Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is a copy of a Substitute "Sequence Listing" in paper form (sheets 1/3 through 3/3) comprising SEQ ID NOS: 1 through 7 for the above-identified patent application as required by 37 C.F.R. §§ 1.825(a) and 1.821(c), and a copy of the Substitute "Sequence Listing" in computer readable form as required by 37 C.F.R. §§ 1.825(b) and 1.821(e). Please replace the Substitute "Sequence Listing" filed on January 5, 2004 (sheets 1/3 through 3/3) with the attached Substitute "Sequence Listing."

A Request for Continued Examination (RCE), an Amendment under 37 C.F.R. § 1.114 and appropriate fees are being filed concurrently with the Substitute Sequence Listing.

As required by 37 C.F.R. § 1.825(b), Applicants' Attorney hereby states that the contents of the Substitute "Sequence Listing" in paper form and in the computer readable form submitted herewith are the same and, as required by 37 C.F.R. § 1.825(a), also states that the submission includes no new matter.

The attached Substitute "Sequence Listing" recites that SEQ ID NO: 6, which consists of the 23 amino acid sequence Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val, has an amide at the C-terminus. Support for SEQ ID NO: 6 is found in the specification, for example, at page 8, lines 1-3, where it is stated that SEQ ID NO: 6 has the identical amino acid sequence of SEQ ID NO: 5 and also contains a C-terminal amide.

The attached Substitute "Sequence Listing" adds SEQ ID NO: 7 which consists of the 23 amino acid sequence Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val and is amidated with NH₂ at the C-terminus. Support for SEQ ID NO: 7 is found in the specification, for example, in originally filed Claims 15, 39-40 and 44-46, where the amino acid sequence Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val-CONH₂ is recited.

The attached Substitute "Sequence Listing" also recites nomenclature that is more commonly used in the art for SEQ ID NO: 7. That is, a molecule amidated with "-NH₂" at the C-terminus means that the -COOH group at the C-terminus is replaced with -CONH₂. No new matter has been added with the Substitute "Sequence Listing".

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By 

Helen Lee

Registration No. 39,270

Telephone: (978) 341-0036

Facsimile: (978) 341-0136

Concord, MA 01742-9133

Date: July 6, 2004